Cite
HARVARD Citation
Platt, H. et al. (2022). A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 40 (1), pp. 162-172. [Online].